Albertsons Companies, Inc. - 10-Q Filing Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 6, 2025 (Fiscal Q2 2025) and the 28 weeks ended September 6, 2025. Albertsons Companies, Inc. is a major U.S. food retailer operating 2,257 stores across 35 states and the District of Columbia under banners including Albertsons, Safeway, and Vons. The company operates 1,720 pharmacies and serves approximately 36.9 million customers weekly.
Key Financial Metrics
| Metric | 12 Weeks Ended Sept 6, 2025 | 28 Weeks Ended Sept 6, 2025 |
|---|---|---|
| Net Sales and Other Revenue | $18,915.8 million | $43,796.6 million |
| Gross Margin | $5,106.6 million (27.0%) | $11,844.9 million (27.0%) |
| Operating Income | $295.3 million | $744.6 million |
| Net Income | $168.5 million | $404.9 million |
| Diluted EPS | $0.30 | $0.71 |
| Adjusted EBITDA | $848.4 million | $1,959.4 million |
| Cash from Operating Activities | N/A (Quarterly) | $1,282.0 million |
| Total Debt (Carrying Value) | $8,126.5 million | $8,126.5 million |
| Cash and Cash Equivalents | $270.6 million | $270.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.0% year-over-year (YoY) for the quarter and 2.3% for the 28-week period. Identical sales (excluding fuel) rose 2.2% for the quarter, driven primarily by strong pharmacy sales growth.
- Digital Expansion: Digital sales (including Drive Up & Go and home delivery) surged 23% YoY. Loyalty membership grew 13% to 48.7 million members.
- Margin Pressure: Gross margin rate decreased to 27.0% from 27.6% YoY. This was attributed to the mix shift toward lower-margin pharmacy sales, increased delivery/handling costs from digital growth, and LIFO expenses ($11.0 million for the quarter).
- Expense Management: Selling and administrative expenses decreased as a percentage of sales (25.4% vs. 25.8% YoY) due to leveraging employee costs and lower merger-related costs, partially offset by higher business transformation costs.
- Impairment Gains/Losses: The company recorded a net gain of $27.5 million for the 28-week period, primarily from real estate asset sales, compared to a net loss of $49.2 million in the prior year period which included significant micro-fulfillment center impairments.
Guidance, Outlook, and Risks
Capital Allocation: The company repurchased 25.7 million shares for $550.1 million during the first 28 weeks. On October 14, 2025, the Board authorized an increase in the share repurchase program to $2.75 billion and entered into a $750 million accelerated share repurchase agreement. Dividends paid were $169.6 million ($0.30 per share) for the 28-week period.
Merger Litigation: Following the termination of the merger with Kroger in December 2024 due to regulatory injunctions, Albertsons is litigating against Kroger for breach of contract, seeking the $600 million termination fee plus additional damages. Trial is scheduled for October 2026. The company has recorded an estimated liability for related legal costs but believes Kroger is responsible for the termination fee.
Legal Contingencies:
- False Claims Act (FCA): Two qui tam actions regarding pharmacy pricing are pending. The company prevailed at trial in the Schutte case in March 2025, but the relators have filed a motion for a new trial on damages. The Proctor trial is scheduled for June 2026.
- Opioid Litigation: The company is a defendant in approximately 81 suits. Discovery is ongoing in bellwether cases in Texas and California.
- PBM Litigation: A lawsuit regarding prescription drug pricing reporting is stayed through September 2025 for settlement discussions, with a trial date set for February 2027.
Outlook: Management estimates liquidity needs for the next 12 months to be between $6.5 billion and $7.0 billion, covering working capital, capex, debt service, and shareholder returns. The company believes it has adequate cash flow to maintain debt ratings.
Investor Verification Checklist
- Merger Litigation Outcome: Verify the status of the lawsuit against Kroger regarding the $600 million termination fee and potential additional damages.
- Pharmacy Pricing Litigation: Monitor the resolution of the Schutte motion for a new trial and the upcoming Proctor trial, as damages could be substantial.
- Margin Sustainability: Assess whether the company can offset the margin pressure from digital delivery costs and pharmacy mix shifts through productivity initiatives.
- Debt Refinancing: Review the terms of the new 2033 Notes ($600 million) and the amended ABL Facility extended to 2030.
- Share Repurchase Execution: Track the execution of the newly authorized $750 million accelerated share repurchase and the expanded $2.75 billion program.